25 citations
,
June 2019 in “Endocrine Related Cancer” Mutations in certain receptors can cause diseases and offer new treatment options.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” Steroid-producing capabilities in certain cancers may contribute to treatment resistance.
13 citations
,
December 2012 in “Canadian Urological Association Journal” 5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
37 citations
,
October 2006 in “Steroids” New sulfur-containing steroid analogs show promise for more targeted medical treatments.
12 citations
,
March 2010 in “Asian Journal of Animal and Veterinary Advances” Young and adult hamsters both respond similarly to testosterone and finasteride treatments, but young hamsters aren't good for testing the inhibitory activity of a specific enzyme.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
January 2022 in “Skin appendage disorders” Finasteride is effective for male hair loss, but it may cause fertility issues, mental health problems, and rarely, breast growth. Regular health checks can reduce the risk of prostate cancer. Patient understanding and involvement in treatment is important.
56 citations
,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
17 citations
,
June 2012 in “European journal of medicinal chemistry” New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
May 2023 in “MQRInvestigar” A young dog with an enlarged prostate and cysts improved significantly after treatment and surgery.
12 citations
,
January 2005 in “Journal of Cosmetic Dermatology” AGA affects many, progresses differently, and early treatment is crucial.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
March 2016 in “National Repository of Dissertations in Serbia” Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
30 citations
,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
17 citations
,
August 2019 in “Archives of Cardiovascular Diseases” Low testosterone in men is a risk factor for a specific heart rhythm issue, and testosterone treatment may help prevent it.
5 citations
,
August 2024 in “Drug Discovery Today” Computational methods help design drugs targeting prostate cancer proteins.
November 2011 in “国际泌尿系统杂志” Intraprostatic injection and high-frequency thermotherapy are more effective for treating prostatitis after TURP than antibiotics, tamsulosin, and finasteride.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
9 citations
,
January 2009 in “PubMed” Finasteride treatment can decrease certain steroids and increase others, possibly leading to depression symptoms in some cases.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
2 citations
,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
June 2023 in “SPIRE - Sciences Po Institutional REpository” Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.
451 citations
,
March 2005 in “Endocrine Reviews” The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.